T follicular helper cells: linking cancer immunotherapy and immune-related adverse events (vol 9, e002588, 2021)

被引：0
|
作者：
Baumjohann, D.
Brossart, P.
机构：
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2021年 / 9卷 / 08期
关键词：
D O I：
10.1136/jitc-2021-002588corr1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Tofacitinib for the treatment of immune-related adverse events in cancer immunotherapy: a multi-center observational study
    Liu, Qing
    Liu, Mengling
    Zou, Zhiguo
    Lin, Jinyi
    Zhang, Ningping
    Zhao, Lin
    Zhou, Jiahua
    Zhou, Haojie
    Zhou, Xin
    Jiao, Xiaodong
    Yu, Yiyi
    Liu, Tianshu
    JOURNAL OF TRANSLATIONAL MEDICINE, 2024, 22 (01)
  • [42] Rheumatic immune-related adverse events associated with cancer immunotherapy: A nationwide multi-center cohort
    Roberts, Janet
    Ennis, Daniel
    Hudson, Marie
    Ye, Carrie
    Saltman, Alexandra
    Himmel, Megan
    Rottapel, Robert
    Pope, Janet
    Hoa, Sabrina
    Tisseverasinghe, Annaliese
    Fifi-Mah, Aurore
    Maltez, Nancy
    Jamal, Shahin
    AUTOIMMUNITY REVIEWS, 2020, 19 (08)
  • [43] Treatment of rheumatic immune-related adverse events due to cancer immunotherapy with immune checkpoint inhibitors—is it time for a paradigm shift?
    Katerina Chatzidionysiou
    Matina Liapi
    Georgios Tsakonas
    Iva Gunnarsson
    Anca Catrina
    Clinical Rheumatology, 2021, 40 : 1687 - 1695
  • [44] Tissue-resident memory T cells in immune-related adverse events: friend or foe?
    Reschke, Robin
    Gajewski, Thomas F.
    ONCOIMMUNOLOGY, 2023, 12 (01):
  • [45] Tissue-Resident T Cells in Clinical Response and Immune-Related Adverse Events of Immune Checkpoint Blockade
    Zhao, Ye
    Wucherpfennig, Kai W.
    CLINICAL CANCER RESEARCH, 2024, 30 (24) : 5527 - 5534
  • [46] Evaluating immune-related adverse events (irAEs) in a real-world cohort with lung cancer receiving immunotherapy
    Hu, Xiao
    Pan, Stacey
    Salei, Yana V.
    Lin, Jeffrey H.
    Parsons, Susan K.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E32 - E32
  • [47] Serum cytokine levels for predicting immune-related adverse events and the clinical response in lung cancer treated with immunotherapy
    Zhao, Ni
    Yi, Ye
    Cao, Wen
    Fu, Xiao
    Mei, Nan
    Li, Chunli
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [48] Treatment of rheumatic immune-related adverse events due to cancer immunotherapy with immune checkpoint inhibitors-is it time for a paradigm shift?
    Chatzidionysiou, Katerina
    Liapi, Matina
    Tsakonas, Georgios
    Gunnarsson, Iva
    Catrina, Anca
    CLINICAL RHEUMATOLOGY, 2021, 40 (05) : 1687 - 1695
  • [49] Serum cytokine levels for predicting immune-related adverse events and the clinical response in lung cancer treated with immunotherapy (vol 12, 923531, 2022)
    Zhao, Ni
    Yi, Ye
    Cao, Wen
    Fu, Xiao
    Mei, Nan
    Li, Chunli
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [50] Genetic alteration profile and T Cell receptor repertoire in severe immune-related adverse events during checkpoint immunotherapy
    Hu, Y.
    Hu, Z.
    Zhang, F.
    Han, X.
    Ma, Z.
    Tao, H.
    Lin, Y.
    Chen, S.
    ANNALS OF ONCOLOGY, 2024, 35 : S699 - S699
12345